Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 4/20 | 0.51 |
| ▸ | CA1 | P00915 | 4/20 | 0.51 |
| ▸ | CA2 | P00918 | 4/20 | 0.51 |
| ▸ | CA3 | P07451 | 4/20 | 0.51 |
| ▸ | CA6 | P23280 | 4/20 | 0.51 |
| ▸ | CA5A | P35218 | 4/20 | 0.51 |
| ▸ | CA7 | P43166 | 4/20 | 0.51 |
| ▸ | CA13 | Q8N1Q1 | 4/20 | 0.51 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.51 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.51 |
| ▸ | CA4 | P22748 | 3/20 | 0.48 |
| ▸ | CA9 | Q16790 | 3/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | PYGL | P06737 | 1/20 | 0.44 |
| ▸ | BTK | Q06187 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL89901 | 0.80 | MEN1 (0.56) | HPGDALDH1A1KDM4EMAPTP2RX7 | |
| SCHEMBL89147 | 0.75 | POLB (0.60) | ALDH1A1KDM4EMAPTP2RX7SMN1; SMN2 | |
| SCHEMBL13618139 | 0.74 | P2RX7 (0.46) | HPGDALDH1A1KDM4EMAPTP2RX7 | |
| SCHEMBL8288031 | 0.72 | NPC1 (0.70) | HPGDALDH1A1SMN1; SMN2PTGS2 | |
| SCHEMBL8265618 | 0.72 | L3MBTL1 (0.42) | HPGDALDH1A1KDM4EMAPTBTK | |
| SCHEMBL13538061 | 0.72 | HPGD (0.51) | HPGDP2RX7SMN1; SMN2 | |
| SCHEMBL89853 | 0.71 | CYP2C9 (0.39) | HPGDALDH1A1MAPTSMN1; SMN2KMT2A | |
| SCHEMBL18150374 | 0.71 | HPGD (0.49) | HPGDALDH1A1KDM4EMAPTCA12 | |
| SCHEMBL31557909 | 0.71 | CA12 (0.43) | HPGDMAPTCA12CA1CA2 | |
| SCHEMBL31557889 | 0.71 | CA12 (0.43) | HPGDMAPTCA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| EP-2177518-A1 | Organic compounds | Novartis AG (CH) | 2010-04-21 | — | — | EP | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
| WO-2006069788-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | HPGD 723/4885ALDH1A1 38/4885KDM4E 1650/4885 |
| US-20110263560-A1 | Organic Compounds | REN, ACE, OTC | HPGD 343/4885ALDH1A1 21/4885KDM4E 1140/4885 |
| US-20090312304-A1 | ORGANIC COMPOUNDS | REN, ACE, PIGO | HPGD 225/4885ALDH1A1 36/4885KDM4E 2265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.